Polyrizon Secures European Patent Publication for Nasal Drug Delivery Tech
Event summary
- Polyrizon's European patent application (EP 4751737) for mucoadhesive nasal drug delivery technology published on June 10, 2026.
- Patent covers Trap & Target™ platform, designed to enhance nasal drug absorption and retention.
- Technology aims to address limited residence time of drugs in nasal cavity.
- Patent still undergoing European examination process; if granted, will support commercialization efforts.
The big picture
Nasal drug delivery is gaining traction as a non-invasive alternative to oral administration, offering faster absorption and avoiding gastrointestinal degradation. Polyrizon's patent application strengthens its position in this growing market, particularly as it seeks to address the challenge of limited drug retention in the nasal cavity. The technology could become a key differentiator in partnerships with pharmaceutical companies developing nasal formulations.
What we're watching
- Patent Approval Timing
- The pace at which the European examination process concludes will determine Polyrizon's IP protection timeline.
- Commercialization Path
- Whether Polyrizon can leverage this patent to secure pharmaceutical partnerships or accelerate product development.
- Market Differentiation
- How effectively Polyrizon's mucoadhesive technology can compete against existing nasal drug delivery solutions.
Related topics